CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $3.1B, above the global median of $1.2B
- FinancialsAltman Z-Score 3.42: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
20.78BCNY3.10B · vs all stocks (USD)
Trailing P/E
41.25xRevenue (TTM)
16.14BCNY2.41B · vs all stocks (USD)
Profit Margin
3.17%Beta
0.0160xvs all stocks
52-Week Change
131.74%vs all stocks
Market Capitalization
20.78BCNY3.10B · vs all stocks (USD)
Enterprise Value
17.59BCNY2.63B · vs all stocks (USD)
Trailing P/E
41.25xForward P/E
27.50xPEG Ratio
-1.65xPrice to Sales (TTM)
1.29xPrice to Book (MRQ)
3.40xEnterprise to Revenue
1.09xEnterprise to EBITDA
19.89xGross Margin
24.11%Profit Margin
3.17%Operating Margin
6.43%Return on Assets (TTM)
2.92%Return on Equity (TTM)
8.22%Revenue (TTM)
16.14BCNY2.41B · vs all stocks (USD)
Revenue per Share (TTM)
6.25CNYUpdated Sep 21, 2026Quarterly Revenue Growth
4.30%Gross Profit (TTM)
4.10BCNY612.84M · vs all stocks (USD)
EBITDA (TTM)
1.03BCNY153.41M · vs all stocks (USD)
Net Income (TTM)
512.21MCNY76.49M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
432.70%Operating Cash Flow (TTM)
534.63MCNY79.84M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
320.44MCNY47.85M · vs all stocks (USD)
5-Year Average Dividend Yield
0.98%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
774.00MCNYFY2025 · Dec 31, 2025Revenue
15.96BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
11.82BCNYFY2025 · Dec 31, 2025Gross Profit
4.15BCNYFY2025 · Dec 31, 2025Operating Income
730.51MCNY109.09M · vs all stocks (USD)
Pre-tax Income
572.74MCNYFY2025 · Dec 31, 2025Income Tax Expense
173.96MCNYFY2025 · Dec 31, 2025Net Income
398.78MCNYFY2025 · Dec 31, 2025EBIT
615.29MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.03BCNYFY2025 · Dec 31, 2025Research & Development
145.01MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.96BCNYFY2025 · Dec 31, 2025Other Operating Expenses
124.64MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
24.35MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
42.55MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
2.58BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.58BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
398.78MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-37.18MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
472.75MCNYFY2025 · Dec 31, 2025Free Cash Flow
329.36MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.36BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
398.78MCNYFY2025 · Dec 31, 2025Other Non-cash Items
49.84MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
224.21MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-200.08MCNYFY2025 · Dec 31, 2025Capital Expenditures
-143.38MCNYFY2025 · Dec 31, 2025Sale of Investments
293.03KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-143.09MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.35BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.70BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-33.29MCNYFY2025 · Dec 31, 2025Other Financing Charges
-71.67MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-457.19MCNYFY2025 · Dec 31, 2025Shares Outstanding
2.52BSharesUpdated Sep 21, 2026Float Shares
1.31BSharesUpdated Sep 21, 2026% Held by Insiders
52.25%vs all stocks
% Held by Institutions
0.60%vs all stocks
Total Cash (MRQ)
3.38BCNY505.44M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.34CNYUpdated Sep 21, 2026Total Debt (MRQ)
1.31BCNY195.11M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1898xCurrent Ratio (MRQ)
1.51xBook Value per Share (MRQ)
2.42CNYUpdated Sep 21, 2026Total Assets
14.29BCNY2.13B · vs all stocks (USD)
Total Current Assets
10.65BCNYFY2025 · Dec 31, 2025Total Liabilities
7.83BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.63BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
402.98MCNYFY2025 · Dec 31, 2025Total Current Liabilities
7.42BCNYFY2025 · Dec 31, 2025Cash
3.34BCNYFY2025 · Dec 31, 2025Cash Equivalents
96.07MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.44BCNYFY2025 · Dec 31, 2025Accounts Receivable
4.39BCNYFY2025 · Dec 31, 2025Inventory
2.06BCNYFY2025 · Dec 31, 2025Accounts Payable
4.03BCNYFY2025 · Dec 31, 2025Short-term Debt
1.18BCNYFY2025 · Dec 31, 2025Other Current Liabilities
85.25MCNYFY2025 · Dec 31, 2025Long-term Debt
61.64MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
997.76KCNYFY2025 · Dec 31, 2025Common Stock (Book)
2.52BCNYFY2025 · Dec 31, 2025Retained Earnings
2.99BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
6.46BCNY964.98M · vs all stocks (USD)
52-Week Low
2.84CNYUpdated Sep 21, 202652-Week High
9.51CNYUpdated Sep 21, 202652-Week Change
131.74%vs all stocks
Beta
0.0160xvs all stocks
50-Day MA
7.18CNYUpdated Sep 21, 2026200-Day MA
4.41CNYUpdated Sep 21, 2026Avg 10-Day Volume
385.74MSharesUpdated Sep 21, 2026Avg 30-Day Volume
393.14MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.2000CNYUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
High Machinery Share, High Accumulated Depreciation Share, And Elevated Sales-To-Non-Current-Assets
Machines are most of what it owns, mostly written off, and still producing plenty of sales.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.42: safe zoneNotable
Altman Z-Score: 3.42
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $3.1B, above the global median of $1.2BNotable
Market cap (USD): 3,102,734,908.21Global Median: 1,201,862,193
Revenue is $2.41B, above the global median of $558.46MNotable
Revenue (USD): 2,409,442,312.008Global Median: 558,459,881.051
Levered free cash flow is $47.85M, above the global median of $18.92MNotable
Levered free cash flow (USD): 47,851,333.871Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Hybio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tasly Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lepu Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Walvax Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule